In this episode of Denatured presented by Arvinas, Jennifer Smith-Parker speaks to Arvinas President and CEO Randy Teel about the strategic discipline and leadership required to successfully refocus a company on an early-stage pipeline after a lead asset is outlicensed, discontinued or otherwise falls away — an inflection point many biotech and pharma companies face, but few navigate effectively.This episode is presented in partnership with Arvinas. HostJennifer Smith-Parker, Director of Insights, BioSpaceGuestRandy Teel, President and CEO, Arvinas
Podzilla Summary coming soon
Sign up to get notified when the full AI-powered summary is ready.
Free forever for up to 3 podcasts. No credit card required.
Listen to This Episode
More from BioSpace
Capricor and Replimune prep for FDA adcomms, Q2 earnings roll on, Sarepta’s new leader, more
Nordic biotech’s next act: From fragmentation to global force
Q2 earnings underway, FDA’s CRL kerfuffle, IPOs full speed ahead in H2
The future of pain relief: Exploring opioid alternatives
Get summaries like this every morning.
Free AI-powered recaps of BioSpace and your other favorite podcasts, delivered to your inbox.
Free forever for up to 3 podcasts. No credit card required.